FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies

bluebird bio, Inc. (BLUE) on Monday said the U.S. Food and Drug Administration lifted its partial clinical hold on the company's studies evaluating lovotibeglogene autotemcel (lovo-cel) for the treatment of patients below 18 years with sickle cell disease (SCD).